India is the latest market to introduce an Australian-made treatment, verified to inactivate the COVID-19 virus on surfaces for up to 28 days.
The Hygiene Labs A333 Antimicrobial Shield is widely used by major clients including Qantas, the national airlines of Fiji and Nauru, the Royal Flying Doctor Service, and major maritime and road fleet operators to help strengthen their existing hygiene protocols.
Now, to help minimise the risk of transmission in India, both fogging and our hospital grade surface applications are being used by tens of thousands of people to enhance personal hygiene and to protect their homes, vehicles and offices. A growing number of enterprises, including auto dealerships and government departments across Gujarat, Mumbai, Delhi, Madhyapradesh, West Bengal, Punjab and Maharastra, are also using the treatment to protect properties and vehicle fleets.
Aman Singh, Hygiene Labs’ exclusive partner in India, said consumer demand for personal supplies of the antimicrobial shield had risen 112 per cent in the past year.
“We see even greater benefits across India expanding the use of this product to Indian industry,” said Mr Singh.
“With verified 28-day effectiveness, and increasing use by major organisations across the Asia-Pacific region, we are confident we can provide extended protection throughout India across passenger transport modes, and in locations including airports and transit terminals, retail outlets, hospitality premises, entertainment venues and industrial facilities.”
The Hygiene Labs treatment, which attracts and punctures pathogens on a microscopic ‘bed of nails’, has been independently evaluated and certificated by Eurofins, one of the world’s largest bioanalytical testing organisations, and listed by Australia’s medical products regulator, the Therapeutic Goods Administration.
Mark Pettitt, Group Managing Director of Hygiene Labs, said: “While vaccines are gradually introduced worldwide, robust hygiene protocols will remain extremely important to help maximise protection of communities and economies against further transmission of COVID, and damaging new rounds of social lockdowns.
“With verified 28-day effectiveness, we are confident that our antimicrobial shield treatment can strengthen hygiene protocols throughout India, not only for individual consumers but also across major sectors including all modes of passenger transport, and in locations including airports and transit terminals, retail outlets, hospitality premises, entertainment venues and industrial facilities.”